2000
Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans
Coulie B, Szarka L, Camilleri M, Burton D, McKinzie S, Stambler N, Cedarbaum J. Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology 2000, 119: 41-50. PMID: 10889153, DOI: 10.1053/gast.2000.8553.Peer-Reviewed Original ResearchConceptsNeurotrophic factorStool frequencyColonic transitR-metHuBDNFHealthy subjectsBrain-derived neurotrophic factorHuman brain-derived neurotrophic factorHuman gut motilityOverall colonic transitPassage of stoolRecombinant human brain-derived neurotrophic factorGastrointestinal motor functionSmall bowel transitInjection site reactionsWeeks of treatmentNeurotrophic factor 3Neurotrophin administrationBowel transitRandomized studyGut motilityColonic emptyingSite reactionsMotor functionConstipationHealthy people
1994
The effects of ciliary neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease
Mitsumoto H, Ikeda K, Holmlund T, Greene T, Cedarbaum J, Wong V, Lindsay R. The effects of ciliary neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. Annals Of Neurology 1994, 36: 142-148. PMID: 8053649, DOI: 10.1002/ana.410360205.Peer-Reviewed Original ResearchConceptsCiliary neurotrophic factorNeurotrophic factorMotor neuron diseaseHuman ciliary neurotrophic factorGrip strengthNeuron diseaseBody weightWobbler mouse motor neuron diseaseMotor neuron disease modelMouse motor neuron diseaseFirst neurotrophic factorMean grip strengthImproved muscle strengthVehicle-treated animalsWeeks of treatmentMuscle twitch tensionSurvival-promoting effectsWobbler mouse modelRat ciliary neurotrophic factorMotor dysfunctionControl miceMuscle strengthDisease progressionMotor neuronsTwitch tension
1990
L-Deprenyl, Levodopa Pharmacokinetics, and Response Fluctuations in Parkinson's Disease.
Cedarbaum JM, Silvestri M, Clark M, Harts A, Kutt H. L-Deprenyl, Levodopa Pharmacokinetics, and Response Fluctuations in Parkinson's Disease. Clinical Neuropharmacology 1990, 13: 29. PMID: 2106391, DOI: 10.1097/00002826-199002000-00003.Peer-Reviewed Original ResearchConceptsParkinson's diseaseResponse fluctuationsL-deprenylTherapeutic response fluctuationsTotal levodopa doseOpen-label trialPlasma levodopa concentrationsPlasma levodopa levelsEffect of deprenylWeeks of treatmentDaily levodopaLevodopa doseLevodopa pharmacokineticsPeripheral pharmacokineticsAction of MAOLevodopa treatmentMost patientsDOPAC levelsLevodopa levelsDopaminergic activityLevodopa concentrationsMild endDose failureTherapeutic actionPatients